WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
VRDN
VIRIDIAN THERAPEUTICS INC
United States
$1.10B62,767,57067.46%32.54%Net BuyingNet Buying
OCS
OCULIS HOLDING AG
Switzerland
$441.63M36,649,70510.87%0.00%
CRNX
CRINETICS PHARMACEUTICALS INC
United States
$3.26B69,596,20285.02%14.98%Net SellingNet Selling
PRTC
PURETECH HEALTH PLC
United States
$793.91M278,566,3060.00%0.00%
ZVRA
ZEVRA THERAPEUTICS INC
United States
$210.07M36,218,16435.01%33.38%Net Buying
STTK
SHATTUCK LABS INC
United States
$424.42M47,474,78356.96%26.50%Net SellingNet Selling
IFRX
INFLARX NV
Germany
$90.68M58,883,27229.00%0.00%
VCYT
VERACYTE INC
United States
$1.66B75,067,82364.44%35.56%Net SellingNet Selling
MGNX
MACROGENICS INC
United States
$919.00M62,432,01372.53%27.47%Net BuyingNet Selling
CMRX
CHIMERIX INC
United States
$94.56M89,210,35645.42%31.91%Net BuyingNet Selling
DTIL
PRECISION BIOSCIENCES INC
United States
$93.78M6,916,23953.55%46.45%Net SellingNet Selling
BLUE
BLUEBIRD BIO INC
United States
$139.95M109,336,21191.17%8.83%Net SellingNet Selling
DNTH
DIANTHUS THERAPEUTICS INC
United States
$880.40M29,346,76026.69%73.31%Net BuyingNet Buying
CASI
CASI PHARMACEUTICALS INC
China
$48.30M13,378,1750.35%99.65%
BOLT
BOLT BIOTHERAPEUTICS INC
United States
$53.38M38,127,74054.74%45.26%Net Selling
NTBL
NOTABLE LABS LTD
Israel
$15.93M9,001,3202.63%97.37%Net SellingNet Selling
ATAI
ATAI LIFE SCIENCES NV
United States
$327.07M166,026,3967.99%37.99%Net Buying
LQDA
LIQUIDIA CORP
United States
$1.12B76,027,77637.69%62.31%Net BuyingNet Selling
AUPH
AURINIA PHARMACEUTICALS INC
Canada
$724.53M144,617,76236.80%3.18%Net SellingNet Selling
CRBU
CARIBOU BIOSCIENCES INC
United States
$464.22M90,314,50176.47%8.74%Net BuyingNet Buying
YMAB
Y-MABS THERAPEUTICS INC
United States
$711.82M43,777,10546.22%39.32%Net BuyingNet Selling
BEAM
BEAM THERAPEUTICS INC
United States
$2.70B81,657,71478.64%21.36%Net SellingNet Selling
QNCX
QUINCE THERAPEUTICS INC
United States
$45.44M42,868,94715.43%84.57%Net BuyingNet Buying
CYCN
CYCLERION THERAPEUTICS INC
United States
$8.67M2,710,0969.83%90.17%Net Buying
ARVN
ARVINAS INC
United States
$2.81B68,083,92874.74%25.26%Net SellingNet Selling
KROS
KEROS THERAPEUTICS INC
United States
$2.38B35,982,62870.92%29.08%Net Buying
CCCC
C4 THERAPEUTICS INC
United States
$560.47M68,600,66968.39%25.29%Net BuyingNet Selling
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
United States
$7.07M1,356,6261.45%3.94%Net Buying
CALT
CALLIDITAS THERAPEUTICS AB
Sweden
$625.89M59,580,0871.42%0.00%
INO
INOVIO PHARMACEUTICALS INC
United States
$324.38M23,370,36561.56%38.44%Net SellingNet Selling
LYEL
LYELL IMMUNOPHARMA INC
United States
$566.63M254,096,31151.66%46.21%Net Selling
XOMA
XOMA CORP
United States
$279.60M11,625,82617.69%82.31%Net Buying
CUE
CUE BIOPHARMA INC
United States
$91.94M48,643,31630.59%9.31%Net Buying
GLYC
GLYCOMIMETICS INC
United States
$193.35M64,450,38535.53%64.47%Net Buying
ARQT
ARCUTIS BIOTHERAPEUTICS INC
United States
$959.42M96,813,36373.21%26.79%Net BuyingNet Selling
IKNA
IKENA ONCOLOGY INC
United States
$68.53M48,258,11166.60%18.22%
ALLO
ALLOGENE THERAPEUTICS INC
United States
$755.84M169,091,99260.41%39.59%Net SellingNet Selling
GTHX
G1 THERAPEUTICS INC
United States
$225.50M52,199,39424.18%47.08%Net SellingNet Selling
NTLA
INTELLIA THERAPEUTICS INC
United States
$2.64B96,106,40568.94%31.06%Net SellingNet Selling
OCUL
OCULAR THERAPEUTIX INC
United States
$1.35B148,627,43949.43%21.84%Net BuyingNet Buying
PGEN
PRECIGEN INC
United States
$360.93M248,919,09625.15%72.66%Net BuyingNet Buying
DNLI
DENALI THERAPEUTICS INC
United States
$2.86B139,160,23956.48%43.52%Net SellingNet Selling
SWTX
SPRINGWORKS THERAPEUTICS INC
United States
$3.63B73,786,84564.08%35.92%Net SellingNet Selling
TFFP
TFF PHARMACEUTICALS INC
United States
$14.29M2,365,3433.16%96.84%Net Buying
QTTB
Q32 BIO INC
United States
$55.03M3,229,64147.07%52.93%Net SellingNet Selling
MRNA
MODERNA INC
United States
$40.71B382,073,20867.29%21.68%Net SellingNet Selling
MIST
MILESTONE PHARMACEUTICALS INC
Canada
$95.14M53,149,77833.44%24.16%
TCRT
ALAUNOS THERAPEUTICS INC
United States
$29.04M16,041,80453.35%46.65%Net Selling
ABCL
ABCELLERA BIOLOGICS INC
Canada
$1.33B292,782,15240.68%47.55%Net BuyingNet Buying
PLUR
PLURI INC
Israel
$33.43M41,480,1720.58%99.42%
ELDN
ELEDON PHARMACEUTICALS INC
United States
$51.12M24,813,13023.14%76.86%
LYRA
LYRA THERAPEUTICS INC
United States
$371.60M59,743,12370.88%14.48%Net Buying
INVA
INNOVIVA INC
United States
$963.58M63,227,33358.68%41.32%Net BuyingNet Buying
NGNE
NEUROGENE INC
United States
$654.22M12,852,98536.48%63.52%Net Buying
SLRN
ACELYRIN INC
United States
$663.96M98,365,05073.06%26.94%Net BuyingNet Selling
LUMO
LUMOS PHARMA INC
United States
$22.86M8,107,12117.72%82.28%Net SellingNet Selling
VIR
VIR BIOTECHNOLOGY INC
United States
$1.37B135,032,26862.23%37.77%Net SellingNet Selling
LPTX
LEAP THERAPEUTICS INC
United States
$68.10M25,600,13713.55%86.45%
ALPN
ALPINE IMMUNE SCIENCES INC
United States
$2.60B65,546,13659.44%40.56%Net BuyingNet Buying
COCP
COCRYSTAL PHARMA INC
United States
$14.24M10,173,7900.69%99.31%Net Buying
KTTA
PASITHEA THERAPEUTICS CORP
United States
$7.55M1,041,8312.22%97.78%Net Buying
ABSI
ABSCI CORP
United States
$640.62M112,784,57629.91%39.04%Net BuyingNet Buying
IOBT
IO BIOTECH INC
Denmark
$113.97M65,880,91436.62%63.38%Net BuyingNet Selling
CLDX
CELLDEX THERAPEUTICS INC
United States
$2.35B55,900,67982.75%17.25%Net BuyingNet Buying
PMCB
PHARMACYTE BIOTECH INC
United States
$20.06M8,464,82412.86%13.29%
LRMR
LARIMAR THERAPEUTICS INC
United States
$484.24M63,800,01742.05%57.95%Net BuyingNet Buying
TVTX
TRAVERE THERAPEUTICS INC
United States
$586.72M76,098,48559.75%40.25%Net SellingNet Selling
AVXL
ANAVEX LIFE SCIENCES CORP
United States
$417.95M82,112,51131.49%5.04%Net Buying
TBPH
THERAVANCE BIOPHARMA INC
Cayman Islands
$432.04M48,164,70860.71%39.29%Net SellingNet Selling
CABA
CABALETTA BIO INC
United States
$823.00M48,241,61592.00%8.00%Net BuyingNet Buying
MOLN
MOLECULAR PARTNERS AG
Switzerland
$137.99M32,854,2972.91%0.00%
TCRX
TSCAN THERAPEUTICS INC
United States
$380.18M47,882,19666.65%29.73%Net Buying
ENTX
ENTERA BIO LTD
Israel
$59.25M35,481,34111.45%3.46%Net BuyingNet Buying
VRNA
VERONA PHARMA PLC
United Kingdom
$1.30B646,524,95810.44%55.94%Net SellingNet Selling
CRDF
CARDIFF ONCOLOGY INC
United States
$238.58M44,677,16911.85%34.59%Net Buying
ATXS
ASTRIA THERAPEUTICS INC
United States
$772.76M54,903,06167.13%25.09%Net BuyingNet Buying
DNA
GINKGO BIOWORKS HOLDINGS INC
United States
$2.50B2,152,395,78658.22%13.97%Net SellingNet Selling
TRVI
TREVI THERAPEUTICS INC
United States
$237.91M68,960,16722.22%77.78%Net Buying
RIGL
RIGEL PHARMACEUTICALS INC
United States
$259.56M175,377,81260.76%15.75%Net SellingNet Selling
LABP
LANDOS BIOPHARMA INC
United States
$66.95M3,116,7294.53%95.47%
ATOS
ATOSSA THERAPEUTICS INC
United States
$225.55M125,304,06412.74%15.20%Net Buying
APRE
APREA THERAPEUTICS INC
United States
$36.33M5,430,2151.54%98.46%Net BuyingNet Buying
VCEL
VERICEL CORP
United States
$2.51B48,290,16491.23%8.77%Net SellingNet Selling
RLAY
RELAY THERAPEUTICS INC
United States
$1.09B131,179,03472.36%27.64%Net SellingNet Selling
ETNB
89BIO INC
United States
$1.09B93,501,21085.94%14.06%Net BuyingNet Buying
BPMC
BLUEPRINT MEDICINES CORP
United States
$5.81B61,232,29781.64%18.36%Net SellingNet Selling
SVRA
SAVARA INC
United States
$687.98M138,148,14132.29%67.71%Net Buying
AKRO
AKERO THERAPEUTICS INC
United States
$1.42B56,297,52866.82%33.18%Net BuyingNet Buying
EVGN
EVOGENE LTD
Israel
$37.94M50,584,5888.48%0.00%
HOWL
WEREWOLF THERAPEUTICS INC
United States
$276.94M42,737,19148.08%51.92%
TERN
TERNS PHARMACEUTICALS INC
United States
$424.12M64,651,69372.17%27.83%Net Buying
ELVN
ENLIVEN THERAPEUTICS INC
United States
$727.30M41,347,63246.24%53.76%Net SellingNet Selling
LSTA
LISATA THERAPEUTICS INC
United States
$25.92M8,307,4330.84%99.16%Net SellingNet Selling
ACAD
ACADIA PHARMACEUTICALS INC
United States
$3.05B164,771,52171.23%28.77%Net BuyingNet Selling
TTNP
TITAN PHARMACEUTICALS INC
United States
$5.38M750,8152.50%97.50%Net Selling
ANAB
ANAPTYSBIO INC
United States
$602.70M26,763,08141.94%58.06%Net SellingNet Selling
DMAC
DIAMEDICA THERAPEUTICS INC
United States
$105.14M37,958,00010.12%55.46%Net BuyingNet Buying
FDMT
4D MOLECULAR THERAPEUTICS INC
United States
$1.59B49,778,12783.80%16.20%Net BuyingNet Selling
APLS
APELLIS PHARMACEUTICALS INC
United States
$7.09B120,581,74974.88%25.12%Net BuyingNet Selling
CVAC
CUREVAC NV
Germany
$678.37M223,883,0849.84%0.00%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Mar 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -18.97% over the past year, underperforming other biotech stocks by -15 percentage points.

Incyte has an average 1 year price target of $73.92, an upside of 29.75% from Incyte's current stock price of $56.97.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Incyte, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 22 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock return 9.03% over the past year, overperforming other biotech stocks by 13 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $38.00, an upside of 13.16% from Harmony Biosciences Holdings's current stock price of $33.58.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 42.86% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 14.29% have issued a Sell rating, and 14.29% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 32.24% over the past year, overperforming other biotech stocks by 37 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 120.19% from Voyager Therapeutics's current stock price of $9.31.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 11.65%.

Carisma Therapeutics's dividend payout ratio of -9.6% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 43.75%, which is 32 percentage points higher than the biotech industry average of 11.65%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.32%, which is -10 percentage points lower than the biotech industry average of 11.65%.

Royalty Pharma's dividend payout ratio of 23.6% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 0.36% in the last day, and up 0.93% over the last week. Avalo Therapeutics was the among the top gainers in the biotechnology industry, gaining 357.89% yesterday.

Avalo shares are trading higher after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 32.24% in the past year. It has overperformed other stocks in the biotech industry by 37 percentage points.

2. Bionomics Limited (NASDAQ:BNOX)


Bionomics Limited (NASDAQ:BNOX) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Bionomics Limited has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Bionomics Limited's stock has dropped -52.75% in the past year. It has underperformed other stocks in the biotech industry by -48 percentage points.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -18.07% in the past year. It has underperformed other stocks in the biotech industry by -14 percentage points.

Are biotech stocks a good buy now?

47.27% of biotech stocks rated by analysts are a buy right now. On average, analysts expect biotech stocks to rise by 65.07% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.26x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.